BMI body mass index; CT computed Tomography; ICU intensive care unit;
BiPAP Bi-level Airway Positive Pressure; *censored means patients
without outcome results
For secondary endpoints, AZM-Corticosteroid decreased the length of
hospital stay in 1.5 day (𝛃 -1.5 95%CI -4.9 to 1.9), while HCQ use
increased in 6.9 days (𝛃 6.9 95%CI 3.6 to 10.3). AZM-Corticosteroid and
therapeutic anticoagulation combination reduced the ICU length stay in
1.5 day (𝛃 -1.5 95%CI -9.7 to 6.7) and MV in 4 days (𝛃 -4.0 95%CI
-13.4 to 5.3), however, this effect was not observed when HCQ was
associated (Figure 3). For the AZM-Corticosteroid and therapeutic
anticoagulation the mean length of ICU stay was 15.9 days, but when HCQ
was included, this time was increased to 40.3 days (Figure 3). There was
a trend to more time in MV in obese patients. All models were adjusting
for sex, age, obesity, pulmonary involvement, D-dimers, CRP, oxygen
support without positive pressure (nasal catheter and Hudson mask) and
length of hospital stay. Regarding HCQ have been used or not, the
comparability of the groups was verified in relation to the clinical
predictors for mortality, where there was no difference was observed
among those who received the drug or not between those treated or not
with HCQ.